Rubric Capital Management LP Takes $5 Million Position in Eupraxia Pharmaceuticals Inc. $EPRX

Rubric Capital Management LP purchased a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 691,170 shares of the company’s stock, valued at approximately $5,004,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Guardian Wealth Advisors LLC NC bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at $76,000. Aptus Capital Advisors LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter worth $76,000. Bank of America Corp DE boosted its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the third quarter valued at $71,000. Finally, Geode Capital Management LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $105,000.

Eupraxia Pharmaceuticals Stock Up 6.2%

EPRX stock opened at $6.17 on Tuesday. The business has a 50 day moving average of $6.51 and a 200 day moving average of $7.33. The firm has a market cap of $401.17 million, a PE ratio of -5.88 and a beta of 1.05. Eupraxia Pharmaceuticals Inc. has a twelve month low of $5.04 and a twelve month high of $9.32. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, May 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, research analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on EPRX. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Finally, Oppenheimer initiated coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an “outperform” rating and a $17.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.